Clinical Trial Update: A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC [Phase 2]

View source ↗

Summary

DexTech Medical AB's Phase IIb study of ODX (Osteodex) in metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ODX (Osteodex)

Snippet

Sponsor: DexTech Medical AB | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: TERMINATED